Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PT-3 GLP-1 Agonist
- Development stage
- Preclinical
- Modality
- Hormonal Peptides → Native Peptides → Peptides, Small Molecules
- Administration
- Oral
01
Overview
PT-3 GLP-1 Agonist is an investigational drug acting as a glucagon-like peptide 1 receptor (GLP-1R) agonist. It mimics the endogenous incretin hormone GLP-1, which is produced in the intestines in response to food intake. By activating the GLP-1 receptor, it stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release, slows gastric emptying, and promotes satiety through central nervous system effects. These combined actions help lower blood glucose levels and reduce appetite, making it potentially useful for treating type 2 diabetes mellitus and obesity. The drug is under development as a novel therapeutic option within the class of GLP-1 receptor agonists.
- Other names
- PT-3 GLP-1 AgonistPT3 GLP-1 AgonistPT 3 GLP-1 Agonist
02
Targets
Beyond the preview
Go deeper on PT-3 GLP-1 Agonist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PT-3 GLP-1 Agonist.